Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-, hydrochloride (1:1)

HCID 59694CAS 102676-31-3

部分構造検索類似構造を探す

基本情報

標準SMILES: Cl.N#Cc1ccc(C2CCCc3cncn32)cc1
InChIKey: UKCVAQGKEOJTSR-UHFFFAOYSA-N
分子式: C14H14ClN3
平均分子量: 259.73 g/mol
単同位体質量: 259.08762513

概要

Fadrozole hydrochloride is an imidazopyridine.

名称と識別子

優先名称: Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-, hydrochloride (1:1)
IUPAC: 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile;hydrochloride

名称と別名

FADROZOLE HYDROCHLORIDE102676-31-3Fadrozole HClAfema4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile hydrochlorideBenzonitrile, 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)-, hydrochloride (1:1)ArensinFadrozole monohydrochlorideH0Q44H4ECQ4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile HydrochlorideBenzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-, hydrochloride (1:1)Hydrochloride, Fadrozole

名称をさらに表示

RefChem:597145Monohydrochloride, Fadrozole631-311-5CGS 16949AFadrozole.HClFadrozole hydrochloride [USAN]DTXSID4020618Fadrozole (hydrochloride)

データベース識別子

CAS: 102676-31-3
PubChem CID: 59694
DTXSID: DTXSID4020618
ChEMBL: CHEMBL468419
ChEBI: CHEBI:31589
UNII: H0Q44H4ECQ
EC Number: 631-311-5

物性

構造計算による物性

極性表面積: 41.6 Å²
水素結合供与体数: 1
水素結合受容体数: 2
回転可能結合数: 1
重原子数: 18
形式電荷: 0
複雑度: 311

安全と法規制

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (100%)

化学と産業

薬理情報

MeSH Pharmacological Classification · 3 件

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.